RECRUITING

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.

Official Title

Allopurinol Improves Diastolic Function in African Americans With Resistant Hypertension

Quick Facts

Study Start:2024-09-30
Study Completion:2026-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05888233

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Veteran
  2. 2. African American
  3. 3. Resistant hypertension diagnosis (defined as blood pressure greater than 140/90 mmHg at 2 clinic visits despite the use of 3 antihypertensive medications at pharmacologically effective doses)
  4. 4. Locale - Birmingham, AL and surrounding areas
  1. 1. History of heart failure
  2. 2. Chronic kidney disease (estimated creatinine clearance \< 60 ml/min)
  3. 3. Chronic steroid therapy
  4. 4. Known coronary artery disease
  5. 5. Known causes of secondary hypertension
  6. 6. Already taking Allopurinol
  7. 1. Claustrophobia
  8. 2. Cardiac implantable electronic device (permanent pacemaker and/or intracardiac defibrillator)
  9. 3. Metal clips and/devices or other item that specifically prohibit safe CMR

Contacts and Locations

Study Contact

Louis J Dellitalia, MD
CONTACT
(205) 933-8101
Louis.Dellitalia@va.gov

Principal Investigator

Louis J Dellitalia, MD
PRINCIPAL_INVESTIGATOR
Birmingham VA Medical Center, Birmingham, AL

Study Locations (Sites)

Birmingham VA Medical Center, Birmingham, AL
Birmingham, Alabama, 35233-1927
United States

Collaborators and Investigators

Sponsor: VA Office of Research and Development

  • Louis J Dellitalia, MD, PRINCIPAL_INVESTIGATOR, Birmingham VA Medical Center, Birmingham, AL

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-30
Study Completion Date2026-05-31

Study Record Updates

Study Start Date2024-09-30
Study Completion Date2026-05-31

Terms related to this study

Keywords Provided by Researchers

  • Hypertension
  • Xanthine Oxidase
  • African American
  • Black
  • Heart Failure

Additional Relevant MeSH Terms

  • Heart Failure Preserved Ejection Fraction
  • Resistant Hypertension